AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
AbCellera (NASDAQ: ABCL) has announced an expansion of its collaboration with Empirico Inc., increasing their targets from five to seven. The partnership utilizes Empirico's Precision Insights Platform for drug target discovery and AbCellera's technology for identifying lead candidate antibodies. The companies successfully identified a lead candidate in under 12 months. The new agreement allows AbCellera to co-develop therapeutic programs, maintaining up to a 50% ownership stake in the resulting antibodies, although financial terms were not disclosed.
- Expanded collaboration with Empirico from five to seven targets.
- Successful identification of a lead candidate in less than 12 months.
- Co-development option allows maintaining up to 50% ownership stake.
- None.
Collaboration expanded from five to seven targets and provides AbCellera the option to co-develop therapeutic programs in partnership with Empirico
Empirico’s platform is designed to uncover causal relationships between genes, proteins, and clinical outcomes by integrating genetic data and health information from millions of individuals together with experimental validation. AbCellera integrates leading technologies to solve all steps in the antibody discovery process and delivers to partners diverse and developable lead candidates against drug targets.
“We have been impressed by Empirico’s ability to discover and validate new drug targets and believe the combination of our respective technologies has great potential to bring new first-in-class treatments to patients,” said
“AbCellera’s technology enables us to extend our competitive advantage in target discovery and validation with best-in-class antibodies to rapidly advance our programs towards the clinic,” said
Under the terms of the expanded agreement, Empirico will have the right to develop and commercialize therapeutic antibodies resulting from the collaboration, and AbCellera has the option to co-develop each therapeutic program to maintain up to a 50 percent ownership stake. Financial terms were not disclosed.
About
Empirico is a next-generation therapeutics company founded on utilizing human genetics, data science, and programmable biology to power novel target discovery and development. Empirico’s Precision Insights PlatformTM, a proprietary human genetics-focused discovery platform, leverages a world-leading dataset, hyperscale infrastructure and algorithmic approaches that encode and enhance human intuition to identify and prioritize therapeutic targets. All potential therapeutic targets are subjected to rigorous in vitro and in vivo experimental validation to elucidate the mechanism by which genetic variation impacts disease risk and provide insights about which therapeutic modality could be ‘programmed’ to mimic or interfere with that mechanism. Empirico is advancing multiple programs across a broad range of indications and therapeutic modalities, both independently and in collaboration with industry partners. Empirico is headquartered in
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220429005732/en/
AbCellera
Media:
Business Development:
Investor Relations:
Empirico
Media:
Business Development:
Source:
FAQ
What did AbCellera announce regarding Empirico on [specific date]?
What is the significance of the Precision Insights Platform in the collaboration?
What is the potential ownership stake for AbCellera in the new agreement with Empirico?
What was the timeline for identifying the lead candidate in the collaboration?
Were the financial terms of the expanded agreement between AbCellera and Empirico disclosed?
